IDH1 Glioma clinical trials
5 active Glioma trials that test for IDH1 in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
- Residual IDH1-Mutant Tumor Cell Quantification Study
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.